medigraphic.com

2006, Number S2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2006; 44 (S2)

Haploidentical transplantations

Sánchez VE, Gómez ME

Language: Spanish
References: 12
Page: 15-18
PDF size: 70.78 Kb.


ABSTRACT

Haploidentical stem cell transplantation is now a viable option for those patients who do not have an HLA compatible sibling or fully matched unrelated donor. Since most patients have at least one haploidentical relative who could serve as a donor, this is immediately available and such availability does not depend on racial or ethnic group. Graft rejection, severe graft versus host disease, post-transplant infectious complications and leukaemia relapse remain the most important complications in the haploidentical setting. Recent modifications and new technological developments have led to more encouraging clinical results. Advances in this method will increase the availability of hematopoietic-cell transplantation as a curative therapy for acute leukaemia. The relative merits of a haploidentical SCT versus mismatched unrelated bone marrow or cord blood donation need to be assessed in prospective, randomized clinical trials.


REFERENCES

  1. Bachar-Lusting E, Rachamim N, LiHW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1: 1268.

  2. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzatti F, et al. Treatment of high-risk acute leukaemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med 1998; 339: 1186-1193.

  3. Rowe JM, Lazarus HM. Genetically haploidentical stem cell transplantation for acute leukaemia. Bone Marrow Transplant 2001; 27: 669-676.

  4. Ringhoffer M, Wiesneth M, von Harsdorf S, Schlenk RF, Schmitt A, Reinhardt P et al. CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. Br J Haematol 2004; 126: 527-535.

  5. Aversa F. New forms of transplantation: haploidentical transplants. Bone Marrow Transplant 2001; 28 (suppl 1): S16-S17.

  6. Aversa F, Berneman ZN, Locatelli F, Martinelli MF, Reisner Y, Tabilio A et al. Fourth international workshop on haploidentical transplants, Naples, Italy, July 8-10, 2004. Blood Cells Molec Dis 2004; 33: 159-175.

  7. Reisner Y, Martinelli MF. Tolerance induction by “megadose” transplants of CD34+ stem cells: a new option for leukaemia patients without an HLA-matched donor. Curr Opin Immunol 2000; 12: 536-541.

  8. Guinan E. Costimulatory blockade as a mechanism of inducing tolerance in the allograft setting. Educational Book of American Society of Hematology; 1999. p. 383-338.

  9. Veys P. The role of haploidentical stem cell transplantation in the management of children with hematological disorders. Br J Haematol 2003; 123: 193-206.

  10. Riddell SR, Greenberg PD. Adoptive immunotherapy with antigen-specific T cells. En: Thomas ED, Blume KJ, Forman SJ (eds). Hematopoietic Cell Transplantation. Oxford: Blackwell Science; 1999. p. 327-341.

  11. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.

  12. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectivenss of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.




2020     |     www.medigraphic.com